Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jong‐Mu Sun's publication output changed over time?
ScholarIQpublication output · 2011–2025
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2025.
1
1
3
1
1
2
1
1
20112015201620192021202220232025
What are the most-cited papers on Jong‐Mu Sun?
ScholarIQmost cited works
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
The Lancet. 20211,629 CitationsOPEN ACCESS
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Manel Esteller, Se‐Hoon Lee, Jung Kyoon Choi
Nature Communications. 2019574 CitationsOPEN ACCESS
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
Journal of Clinical Oncology. 2022315 CitationsOPEN ACCESS
Pembrolizumab for the treatment of non-small cell lung cancer
Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Expert Opinion on Biological Therapy. 2016293 Citations
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Sehhoon Park, Chan‐Young Ock, Hyojin Kim, Sérgio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong‐Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung‐Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung‐Jue Bang, Yoon‐La Choi, Tony Mok, Se‐Hoon Lee
Journal of Clinical Oncology. 2022290 CitationsOPEN ACCESS
Related on ScholarIQ
Samsung Medical Center
Institution
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Paper
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Paper
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Paper
Pembrolizumab for the treatment of non-small cell lung cancer
Paper
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Paper